Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PTT-936, an Alpha Kinase 1 (ALPK1) Activator, Alone or in Combination With Anti-PD-1/L1 in Patients With Locally Advanced or Metastatic Solid Tumors

NCT06244992 is registered in ClinicalTrials.gov with Pyrotech Therapeutics, Inc. as lead sponsor.

NCT NCT06244992
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06244992 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PTT-936, an Alpha Kinase 1 (ALPK1) Activator, Alone or in Combination With Anti-PD-1/L1 in Patients With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Pyrotech Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 26, 2024
Completion date
December 31, 2027
Enrollment
68 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced or metastatic solid tumors